Stock Scorecard

Stock Summary for Jazz Pharmaceuticals plc (JAZZ) - $109.45 as of 7/4/2025 1:25:35 AM EST

Total Score

15 out of 30

Safety Score

55 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for JAZZ

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for JAZZ

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for JAZZ

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for JAZZ

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for JAZZ (55 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for JAZZ

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL ) 7/1/2025 5:28:00 PM
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation 6/30/2025 11:00:00 AM
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation - Avadel Pharmaceuticals ( NASDAQ:AVDL ) 6/30/2025 11:00:00 AM
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer 6/24/2025 12:30:00 PM
Why Is Jazz ( JAZZ ) Up 7.9% Since Last Earnings Report? 6/5/2025 3:30:00 PM
2 Soaring Stocks Wth More Upside Potential 6/5/2025 7:19:00 AM
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study - Jazz Pharmaceuticals ( NASDAQ:JAZZ ) 6/3/2025 6:37:00 PM
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer 6/3/2025 5:00:00 AM
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression ( IHC3+ ) Biliary Tract Cancer 5/30/2025 10:00:00 AM
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression ( IHC3+ ) Biliary Tract Cancer - Zymeworks ( NASDAQ:ZYME ) 5/30/2025 10:00:00 AM

Financial Details for JAZZ

Company Overview
Ticker JAZZ
Company Name Jazz Pharmaceuticals plc
Country USA
Description Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 7/30/2025

Stock Price History
Last Day Price 109.45
Price 4 Years Ago 127.40
Last Day Price Updated 7/4/2025 1:25:35 AM EST
Last Day Volume 327,049
Average Daily Volume 748,335
52-Week High 148.06
52-Week Low 95.49
Last Price to 52 Week Low 14.62%

Valuation Measures
Trailing PE 14.40
Industry PE 21.93
Sector PE 40.90
5-Year Average PE 19.14
Free Cash Flow Ratio 3.56
Industry Free Cash Flow Ratio 17.71
Sector Free Cash Flow Ratio 32.91
Current Ratio Most Recent Quarter 3.38
Total Cash Per Share 30.77
Book Value Per Share Most Recent Quarter 67.75
Price to Book Ratio 1.54
Industry Price to Book Ratio 34.53
Sector Price to Book Ratio 30.76
Price to Sales Ratio Twelve Trailing Months 1.63
Industry Price to Sales Ratio Twelve Trailing Months 121.97
Sector Price to Sales Ratio Twelve Trailing Months 35.60
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 6

Share Statistics
Total Shares Outstanding 60,511,000
Market Capitalization 6,622,928,950
Institutional Ownership 101.94%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.75%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 118.50%
Annual Earnings Growth 35.02%
Reported EPS 12 Trailing Months 7.60
Reported EPS Past Year 1.68
Reported EPS Prior Year 21.19
Net Income Twelve Trailing Months 482,197,000
Net Income Past Year 560,120,000
Net Income Prior Year 414,832,000
Quarterly Revenue Growth YOY -0.50%
5-Year Revenue Growth 13.48%
Operating Margin Twelve Trailing Months -2.90%

Balance Sheet
Total Cash Most Recent Quarter 1,861,946,000
Total Cash Past Year 2,412,864,000
Total Cash Prior Year 1,506,310,000
Net Cash Position Most Recent Quarter -3,474,535,000
Net Cash Position Past Year -3,664,776,000
Long Term Debt Past Year 6,077,640,000
Long Term Debt Prior Year 5,107,988,000
Total Debt Most Recent Quarter 5,336,481,000
Equity to Debt Ratio Past Year 0.40
Equity to Debt Ratio Most Recent Quarter 0.44
Total Stockholder Equity Past Year 4,093,756,000
Total Stockholder Equity Prior Year 3,736,997,000
Total Stockholder Equity Most Recent Quarter 4,174,891,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 1,488,416,000
Free Cash Flow Per Share Twelve Trailing Months 24.60
Free Cash Flow Past Year 1,347,838,000
Free Cash Flow Prior Year 1,068,045,000

Options
Put/Call Ratio 0.50
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.37
MACD Signal -0.46
20-Day Bollinger Lower Band 88.14
20-Day Bollinger Middle Band 116.43
20-Day Bollinger Upper Band 144.72
Beta 0.33
RSI 52.44
50-Day SMA 116.84
150-Day SMA 126.91
200-Day SMA 131.19

System
Modified 7/3/2025 3:08:02 AM EST